564 related articles for article (PubMed ID: 17275793)
21. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
23. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys.
Hurley SD; O'Banion MK; Song DD; Arana FS; Olschowka JA; Haber SN
Exp Neurol; 2003 Dec; 184(2):659-68. PubMed ID: 14769357
[TBL] [Abstract][Full Text] [Related]
24. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model.
Kang JM; Park HJ; Choi YG; Choe IH; Park JH; Kim YS; Lim S
Brain Res; 2007 Feb; 1131(1):211-9. PubMed ID: 17173870
[TBL] [Abstract][Full Text] [Related]
25. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
[TBL] [Abstract][Full Text] [Related]
27. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
28. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
Ito T; Suzuki K; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
[TBL] [Abstract][Full Text] [Related]
29. Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb.
Vroon A; Drukarch B; Bol JG; Cras P; Brevé JJ; Allan SM; Relton JK; Hoogland PV; Van Dam AM
Exp Gerontol; 2007 Aug; 42(8):762-71. PubMed ID: 17592750
[TBL] [Abstract][Full Text] [Related]
30. [Effect of the oil from ganoderma lucidum spores on pathological changes in the substantia nigra and behaviors of MPTP-treated mice].
Zhu WW; Liu ZL; Xu HW; Chu WZ; Ye QY; Xie AM; Chen L; Li JR
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):667-71. PubMed ID: 15958304
[TBL] [Abstract][Full Text] [Related]
31. Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Gao L; Díaz-Martín J; Dillmann WH; López-Barneo J
Neuroscience; 2011 Oct; 193():323-9. PubMed ID: 21782904
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
33. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
34. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Kato H; Kurosaki R; Oki C; Araki T
Brain Res; 2004 Dec; 1030(1):66-73. PubMed ID: 15567338
[TBL] [Abstract][Full Text] [Related]
35. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Liu J; Wang MW; Gu P; Ma QY; Wang YY; Geng Y; Yuan ZY; Cui DS; Zhang ZX; Ma L; Zhang BH; Zhou MG; Zhu AP
Brain Res; 2010 Jul; 1345():213-20. PubMed ID: 20546706
[TBL] [Abstract][Full Text] [Related]
36. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice.
Hong Z; Wang G; Gu J; Pan J; Bai L; Zhang S; Chen SD
Eur J Neurosci; 2007 Sep; 26(6):1500-8. PubMed ID: 17714494
[TBL] [Abstract][Full Text] [Related]
37. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
38. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.
Mitsumoto Y; Watanabe A; Mori A; Koga N
Biochem Biophys Res Commun; 1998 Jul; 248(3):660-3. PubMed ID: 9703982
[TBL] [Abstract][Full Text] [Related]
39. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
